Health

Pfizer boosters ruled OK for high-risk groups

By The Associated Press
Sept. 17, 2021 9 p.m.

After overwhelmingly rejecting a plan to give Pfizer booster shots against COVID-19 to most Americans, an influential federal advisory panel has approved the extra shots for those who are 65 or older or run a high risk of severe disease

Hollie Maloney, a pharmacy technician, loads a syringe earlier this spring with Pfizer's COVID-19 vaccine at the Portland Expo in Portland, Maine. An influential federal advisory panel overwhelmingly rejected a plan Friday, Sept. 17, to offer Pfizer booster shots against COVID-19 to most Americans, dealing a heavy blow to the Biden administration’s effort to shore up people’s protection amid the highly contagious delta variant.

Hollie Maloney, a pharmacy technician, loads a syringe earlier this spring with Pfizer's COVID-19 vaccine at the Portland Expo in Portland, Maine. An influential federal advisory panel overwhelmingly rejected a plan Friday, Sept. 17, to offer Pfizer booster shots against COVID-19 to most Americans, dealing a heavy blow to the Biden administration’s effort to shore up people’s protection amid the highly contagious delta variant.

Robert F. Bukaty / AP

WASHINGTON (AP) — After overwhelmingly rejecting a plan to give Pfizer booster shots against COVID-19 to most Americans, an influential federal advisory panel has approved the extra shots for those who are 65 or older or run a high risk of severe disease.

THANKS TO OUR SPONSOR:

The twin votes Friday represented a blow to the Biden administration’s sweeping effort to shore up nearly all Americans’ protection amid the spread of the highly contagious delta variant. The decision was made by a committee of outside experts who advise the Food and Drug Administration.

The vote recommending the booster shots for older Americans and other high-risk groups helps salvage part of the White House’s campaign but is still be a huge step back from the sweeping plan proposed by administration a month ago to offer booster shots of both the Pfizer and Moderna vaccines to nearly all Americans eight months after they get their second dose.

During several hours of vigorous debate Friday, members of the panel questioned the value of offering boosters to nearly everyone.


THANKS TO OUR SPONSOR:
THANKS TO OUR SPONSOR:

Become a Sustainer now at opb.org and help ensure OPB’s fact-based reporting, in-depth news and engaging programs thrive in 2025 and beyond.
We’ve gone to incredible places together this year. Support OPB’s essential coverage and exploration in 2025 and beyond. Join as a monthly Sustainer now or with a special year-end contribution. 
THANKS TO OUR SPONSOR: